introduction number cancer survivor united state currently exceeds million expected increase million conventional chemotherapy remains mainstay cancer treatment particularly locally advanced metastatic tumor correspondingly global demand chemotherapy estimated rise chemotherapy patient develop cognitive deficit observation known chemotherapy-related cognitive impairment crci colloquially chemobrain. crci affect multiple cognitive domain including memory attention executive function cognitive deficit observed following chemotherapy treatment functionally significant contribute reduced ability function work return work crci may persist decade therapy epidemiologic study found association chemotherapy history subsequent risk dementia radiologic brain alteration following chemotherapy treatment reported decrease grey matter volume density functional/structural connectivity change reduced white matter integrity risk factor developing crci include advanced age low cognitive reserve certain genetic polymorphism e.g apoe4 allele despite projected increase cancer survivor impact crci patient quality life daily functioning pathophysiology crci incompletely understood vivo crci model developed rodent implicated mechanism involving neuroinflammation proinflammatory cytokine oxidative stress dna damage direct cytotoxicity brain cell population dysmyelination neurogenesis among others goal validate drosophila model relevant crci used complementary system investigate mechanism contributing crci chemotherapy-induced neurotoxicity drosophila melanogaster common fruit fly powerful system study human disease approximately human disease-causing gene drosophila orthologs conserved cellular function compared mammalian model organism drosophila rapid generation time shorter life cycle inexpensive grow maintain importantly use drosophila highly amenable forward reverse genetic approach including gene editing fast generation transgenic line tissue- cell type-specific expression gene interest high throughput genetic modifier pharmacologic screen strength drosophila model system resulted important mechanistic insight neurodegenerative neurodevelopmental disorder form iatrogenic neuropathology including chemotherapy-induced peripheral neuropathy highlighting importance practicality crci-relevant drosophila model establish drosophila model relevant crci wanted determine chemotherapy-treated fly recapitulate clinical neuropathologic feature chemotherapy patient thus investigated whether chemotherapy-treated fly show neurologic/neurocognitive deficit evidence neurodegeneration corresponding patient neuroradiology change increased dna damage oxidative stress previously described brain chemotherapy patient result chemotherapy-treated drosophila show neurologic/neurocognitive deficit investigate effect chemotherapy administration fly adult aged day transferred vial containing instant drosophila medium rehydrated chemotherapy-containing aqueous solution vehicle control fly treated day regimen chemotherapy vehicle transferred back vial containing standard cornmeal-agar medium aged day neurologic/neurocognitive testing climbing assay taste memory assay tissue harvesting chemotherapeutic regimen used cisplatin μg/ml cyclophosphamide μg/ml doxorubicin μg/ml survival rate cohort day provided supplemental table climbing assay performed high-throughput screening assay ass general neurologic function based negative geotaxis drosophila i.e intrinsic proclivity climb upwards fly treated chemotherapy aged day showed reduced climbing ability fig comparison vehicle control group reached statistical significance intermediate high dose cisplatin cohort μg/ml low intermediate dose cyclophosphamide cohort μg/ml low intermediate high dose doxorubicin cohort μg/ml trend towards reduced climbing ability chemotherapy cohort also observed day supplemental fig figure chemotherapy-treated drosophila show impaired climbing ability general neurologic readout climbing ability data timepoints shown statistically significant difference observed day data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.00555 considered significant cohort consists replicates 7–12 fly fly total/cohort day post-eclosion genotype 0.00555 asterisk included bar graph full size image taste memory assay performed ass learning memory fig supplemental fig taste memory assay type conditioning test take advantage drosophila proboscis extension reflex per sucrose solution presented tarsus drosophila extend proboscis feed taste memory assay drosophila trained extend proboscis tarsus exposed sucrose solution else labella exposed bitter aversive quinine solution assay evaluates ability fly learn remember aversive stimulus thus extend proboscis importantly fly without intact per pretest phase assay indicating impaired motor ability extend proboscis attenuated taste sensation excluded study trial 1–5 timepoint training phase low dose cisplatin cohort μg/ml significantly higher percent trial positive per compared vehicle control group suggesting learning defect although chemotherapy cohort higher per vehicle control group various timepoints training phase comparison reach statistical significance multiple timepoints test phase chemotherapy-treated fly higher percent trial positive per compared vehicle control group suggesting reduced ability retain memory aversive stimulus statistically significant difference observed high dose doxorubicin cohort minute high dose cisplatin cohort minute intermediate dose cisplatin cohort minute low dose cisplatin cohort minute figure chemotherapy-treated drosophila impaired neurocognitive function assessed taste memory assay neurocognitive defect prominent cisplatin-treated fly statistically significant difference observed minute test phase cisplatin- doxorubicin-treated fly data represented mean sem statistical analysis performed using repeated measure 2-way anova dunnett multiple comparison test cohort consists fly day post-eclosion genotype 0.05 0.01 per proboscis extension reflex full size image overall chemotherapy-treated drosophila demonstrated neurologic neurocognitive deficit assessed climbing assay taste memory assay highlighting relevance drosophila model study crci deficit observed different chemotherapeutic agent range concentration diverse mechanism action particularly prominent following cisplatin treatment cisplatin exposure exacerbates neurodegeneration drosophila treatment cisplatin resulted severe neurologic neurocognitive deficit decided focus subsequent tissue analysis fly given cisplatin assessed neurodegeneration drosophila quantifying number cell caspase activation number brain vacuole used da-gal4 drive ubiquitous expression transgenic caspase reporter uas-cd8-parp-venus uas-cd8-parp-venus reporter fly contain transgenic construct composed extracellular transmembrane domain mouse cd8 fused amino acid sequence human parp includes caspase cleavage site activated endogenous drosophila caspase cleave human parp caspase cleavage site caspase activation assessed using antibody specifically bind cleaved human parp found significantly increased number cell caspase activation high dose cisplatin cohort day intermediate dose cisplatin cohort day low dose cisplatin cohort day compared vehicle control cohort fig brain cell activated caspase predominantly neuron demonstrated double labeling immunofluorescence elav neuron specific marker also included glia fly treated high dose cisplatin also significantly increased brain vacuole compared vehicle control day fig vacuole seen optic lobe central brain including mushroom body formation brain vacuole frequently associated neurodegeneration drosophila summary exposure chemotherapeutic agent cisplatin associated elevated indicator neurodegeneration including caspase activation brain vacuole figure neurodegeneration increased cisplatin-treated drosophila assessed caspase activation fly given cisplatin increase number brain cell caspase activation predominantly elav positive neuron immunofluorescence image brain cisplatin control fly day shown arrow highlight neuron showing caspase activation scale bar data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.0166 considered significant cohort day post-eclosion genotype uas-cd8-parp-venus da-gal4 0.0166 full size image figure neurodegeneration increased cisplatin-treated drosophila assessed brain vacuole fly given cisplatin increase number brain vacuole hematoxylin eosin image brain cisplatin control fly day shown arrow highlight representative vacuole scale bar data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.0166 considered significant cohort day post-eclosion genotype 0.0166 full size image dna damage elevated cisplatin exposure dna damage assessed quantifying percent cell showing phosphorylation serine histone variant h2av ph2av marker dna double-strand break focused quantification anatomically consistent region mushroom body area drosophila brain important learning memory significantly increased percent ph2av positive cell seen high dose cisplatin cohort day intermediate dose cisplatin cohort day compared vehicle control cohort fig ph2av positive brain cell predominantly neuron supported double labeling immunofluorescence neuronal marker elav also included glia thus chemotherapy exposure resulted increased dna damage brain figure dna damage increased cisplatin-treated drosophila fly given cisplatin increase percent ph2av positive cell predominantly elav positive neuron within anatomically consistent region mushroom body immunofluorescence image brain cisplatin control fly day shown arrow highlight representative neuron ph2av punctate staining scale bar data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.0166 considered significant cohort day post-eclosion genotype 0.0166 full size image oxidative stress elevated cisplatin exposure oxidative stress assessed using puckered-lacz puc-lacz gstd1-gfp reporter system puc gene encodes phosphatase downstream target negative regulator jnk signaling pathway activated response oxidative stress activation puc-lacz reporter detected β-galactosidase immunopositivity found fly treated cisplatin increased number brain cell puc-lacz activation compared fly treated vehicle control reaching statistical significance high dose cisplatin cohort day intermediate dose cisplatin cohort day fig double labeling immunofluorescence elav data shown demonstrated puc-lacz activation neuron previously reported gstd1 oxidative stress response gene encodes glutathione s-transferase activation gstd1-gfp reporter detected gfp immunopositivity preliminary immunofluorescence data suggested differential activation gstd1-gfp prominent retina brain following chemotherapy subsequent analysis confirmed cisplatin-treated fly increased cell retina gstd1-gfp activation compared vehicle control reaching statistical significance high dose cisplatin cohort day intermediate dose cisplatin cohort day fig representative gstd1-gfp image shown supplemental fig summary chemotherapy exposure associated elevated marker oxidative stress figure oxidative stress increased cisplatin-treated drosophila assessed puc-lacz activation fly given cisplatin increased brain cell puc-lacz reporter activation indicated β-galactosidase immunopositivity immunohistochemical image brain cisplatin control fly day shown arrow highlight representative cell puc-lacz activation scale bar data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.0166 considered significant cohort day post-eclosion genotype puc-lacz 0.0166 full size image figure oxidative stress increased cisplatin-treated drosophila assessed gstd1-gfp activation fly given cisplatin demonstrate increased number retinal cell gstd1-gfp reporter activation data represented mean sem statistical analysis performed using whitney-mann test bonferroni correction multiple testing corrected value 0.0166 considered significant cohort day post-eclosion genotype gstd1-gfp 0.0166 full size image discussion crci clinically important functionally significant adverse effect chemotherapy observed patient however development effective crci disease-modifying therapy hindered limited understanding pathophysiology crci thus new approach investigate crci needed present working drosophila model relevant crci chemotherapy-induced neurotoxicity generally recapitulates clinical neuropathologic feature described chemotherapy patient used climbing assay high throughput screening test general neurologic function general neurologic readout climbing assay reflects status cns pns neuromuscular system observed neurologic deficit drosophila model following treatment different chemotherapeutic agent diverse mechanism action multiple concentration cisplatin cyclophosphamide doxorubicin commonly administered breast cancer patient patient population studied crci among group chemotherapy whose use associated crci concentration chemotherapy tested informed previously published dos administered drosophila concentration cisplatin ranged μg/ml prior study reported cisplatin regimen μg/ml resulted whole drosophila body concentration comparable used human patient rodent model cisplatin-induced neurotoxicity used taste memory assay evaluate neurocognitive function making assay particularly well-suited model crci importantly unlike method assessing cognition drosophila olfactory conditioning assay aversive phototaxis suppression assay taste memory assay dependent locomotor ability chemotherapy-treated fly showed consistent trend towards worse performance test phase taste memory assay fig supplemental fig becoming statistically significant multiple timepoints memory deficit prominent cisplatin-treated fly assay noise may contributed fluctuation performance training test phase taste memory assay reduced assay sensitivity detect subtle cognitive defect thus follow-up study would recommend increasing cohort size taste memory assay reduce noise cisplatin resulted marked neurocognitive deficit model decided focus neuropathologic evaluation cisplatin-treated fly given chemotherapy patient show radiologic change brain including reduction grey matter volume density interested assessing neurodegeneration chemotherapy-treated drosophila demonstrated increase number cell caspase activation cisplatin exposure finding keeping previous study showing increased apoptosis cell death vulnerable brain cell population following chemotherapy vivo vitro model observed number cell activated caspase elevated acutely cisplatin treatment i.e day remained persistently elevated day thus chemotherapy appears induce long term change promote ongoing caspase activation age supported vacuolar neurodegeneration data showed increase brain vacuole high dose cisplatin group day earlier timepoints presence brain vacuole cortex neuropil plausibly reflects cell death loss axon caspase activation may sensitive/specific vacuole formation detecting neurodegeneration possibly accounting difference two assay overall drosophila model showed increased neurodegeneration number cell caspase activation brain number brain vacuole previously reported chemotherapy patient elevated dna damage oxidative stress frontal lobe cortical neuron compared control patient thus wanted ass whether pathway upregulated crci-relevant drosophila model fly treated cisplatin showed increased dna damage indicated ph2av positivity compared vehicle control similar observation caspase activation dna damage increased acutely cisplatin treatment continued elevated long cessation chemotherapy oxidative stress indicated puc-lacz gstd1-gfp reporter activation brain retina respectively elevated cisplatin-treated fly compared vehicle control statistically significant difference observed day however exclude possibility marker oxidative stress may elevated acutely difference observed drosophila model timing dna damage oxidative stress may implicate certain biological pathway chemotherapy-induced neurotoxicity brain cisplatin known damage nuclear mitochondrial dna data suggest dna damage occurs early chemotherapy exposure cisplatin-induced dna damage promotes production mitochondrial derived reactive oxygen specie time result measurable increase oxidative stress may cause additional dna damage creating positive feedback loop contributes persistently elevated dna damage oxidative stress caspase activation long initial chemotherapy insult removed compelling speculate whether cellular senescence arising setting chemotherapy may role persistent change study limitation firstly data implicate promising molecular pathway crci mechanistic analysis needed determine neurotoxic effect chemotherapy due direct action brain cell population indirect mechanism combination two secondly demonstrate multiple chemotherapeutic agent cause neurologic/neurocognitive deficit drosophila tissue analysis focused cisplatin since resulted significant decrement neurocognitive function although anticipate use drosophila accelerate mechanistic understanding crci emphasize pathophysiology crci multifactorial drosophila may better recapitulate mechanism others blood brain barrier permeability chemotherapeutic agent alteration neurogenesis microglial activation likely contribute crci additional study needed determine whether mechanism appropriately modeled drosophila summary present novel drosophila model relevant crci drosophila model demonstrates neurologic/neurocognitive deficit increased neurodegeneration elevated dna damage oxidative stress recapitulating clinical neuropathologic feature chemotherapy patient drosophila model may thus serve complementary system existing rodent crci model take advantage powerful drosophila genetic tool high throughput screening low operational cost short lifespan model easily adapted test chemotherapeutic drug different concentration timepoints combination also interested dissecting phenotypic difference sex investigating vulnerability chemotherapy-induced injury may mediated sex future drosophila crci study leverage forward reverse genetic approach decipher molecular pathway contributing crci identify specific cell type particularly vulnerable chemotherapy-induced injury use pharmacologic screen identify agent may ameliorate crci investigate mechanistic interaction crci tau pathology synuclein pathology cellular senescence among pathway relevant neurodegeneration material method drosophila stock genetics drosophila cross performed 25°c following stock obtained bloomington drosophila stock center nih p40od018537 indiana university bloomington da-gal4 puc e69 puc-lacz darren williams king college london united kingdom provided uas-cd8-parp-venus stock dirk bohmann university rochester medical center rochester provided gstd1-gfp stock male female fly used experiment chemotherapy regimen maintenance fly appropriate genotype aged day post-eclosion vial containing standard cornmeal-agar medium transferred vial instant medium carolina biological burlington rehydrated chemotherapy-containing aqueous solution vehicle control milli water milliporesigma burlington fly placed day regimen rehydrated instant medium replaced daily following day regimen fly transferred back vial containing standard cornmeal-agar medium aged day post-eclosion testing and/or harvesting histologic study chemotherapeutic agent cisplatin μg/ml doxorubicin μg/ml cyclophosphamide μg/ml dissolved milli water chemotherapeutic agent purchased milliporesigma drug concentration chemotherapeutic agent similar used prior drosophila study aging performed climbing assay fly underwent climbing assay day post-eclosion individual fly tested one timepoint climbing assay performed based standard protocol timepoint treatment cohort 7–12 fly placed individual empty vial total vial least fly tested group vial gently tapped bring fly bottom vial percent fly climbed within recorded climbing assay repeated time vial fly averaged approximately equal proportion male female used cohort taste memory assay taste memory assay performed chemotherapy vehicle control treated fly day post-eclosion based standard protocol minor modification fly starved prior testing transferred empty vial milli water-soaked kimwipes kimberly-clark franklin fly briefly anesthetized fixed glass slide nail polish moved humidified incubator recovery period slide vertically mounted placed dissecting microscope observe fly behavior fly satiated purified water fly satiated min excluded study taste memory assay consists phase pretest phase training phase test phase pretest phase 500mm sucrose solution presented fly tarsus confirm intact proboscis extension reflex per fly negative per excluded study training phase consists trial trial fly tarsus exposed sucrose solution proboscis extended bitter aversive solution quinine presented labellum fly allowed drink quinine solution retracted proboscis trial tarsus labellum washed water fly allowed drink fresh water satiation training trial binned group trial trial 1–5 6–10 11–15 test phase sucrose solution presented tarsus multiple time interval min labellum exposed quinine solution proboscis extended test timepoint fly underwent trial interval trial percent trial positive per recorded fly timepoint test timepoint tarsus washed water fly allowed drink fresh water satiation end test phase fly given sucrose solution confirm intact per fly negative per excluded analysis sucrose quinine solution presented fly droplet end syrinx gauge needle least fly tested per cohort approximately equal proportion male female histology immunohistochemistry immunofluorescence fly harvested day post-eclosion fixed formalin fly head embedded paraffin serially sectioned entire brain retina either thick section processed series xylene ethanol water vacuolar neurodegeneration evaluated brain section stained hematoxylin eosin immunostaining study section incubation following primary antibody performed following routine heat antigen retrieval sodium citrate buffer 6.0 anti-cleaved parp abcam e51 cambridge 1:50,000 immunohistochemistry ihc 1:500 immunofluorescence anti-β-galactosidase promega z3783 madison 1:500 ihc 1:100 anti-gfp neuromab n86/8 davis 1:500 ihc anti-ph2av rockland 600–401-914 pottstown 1:2500 ihc 1:1000 anti-elav developmental study hybridoma bank clone 9f8a9 7e8a10 iowa city 1:5 9f8a9 1:50 7e8a10 ihc slide incubated biotinylated secondary antibody southern biotech birmingham 1:200 marker visualized avidin–biotin complex abc detection system vector laboratory burlingame 3,3′-diaminobenzidine dab ph2av ihc slide counterstained hematoxylin slide incubated alexa fluor-conjugated secondary antibody invitrogen alexa alexa carlsbad 1:200 mounted 4',6-diamidino-2-phenylindole dapi -containing fluoromount medium southern biotech quantification vacuolar neurodegeneration caspase activation puc-lacz activation number vacuole number immunopositive cell throughout entire brain counted per fly average number vacuole immunopositive cell per brain averaged cohort per cohort quantified gstd1-gfp activation counting number gfp immunopositive cell throughout entire retina bilaterally fly average number immunopositive cell bilateral retina averaged cohort per cohort ph2av quantification performed calculating percent ph2av-positive cell within high power field anatomically consistent region mushroom body containing kenyon cell percent ph2av-positive cell averaged cohort per cohort equal number male female evaluated cohort histology immunohistochemistry study ihc slide analyzed using nikon eclipse e600 microscope spot software photo taken olympus dp25 camera photo taken zeiss lsm confocal microscope statistical analysis climbing assay chemotherapy cohort compared vehicle control cohort using whitney-mann test bonferroni correction multiple testing two-sided study-wide level 0.05 considered significant since comparison different chemotherapeutic agent concentration compared control per timepoint corrected value threshold 0.00555 used determine significance taste memory assay chemotherapy cohort compared vehicle control cohort using repeated measure 2-way anova dunnett multiple comparison test value 0.05 considered significant histology immunohistochemistry study chemotherapy cohort compared vehicle control cohort using whitney-mann test bonferroni correction multiple testing 2-sided study-wide level 0.05 significance comparison per timepoint per study concentration cisplatin compared control corrected value threshold 0.0166 used determine significance